Prospectus
Filed with ASX · · 30 pages · English
On 6ix: 6ix.com/news/prospectus-224
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Early Efficacy & Safety Data Planned for XanADu Trial
- Placement Fully Funds Completion of XanADu Alzheimers Trial
- R&D Rebate Received Totalling $1.22 Million
- Quarterly Update & Appendix 4C
- Final Major Market Patent Granted for Xanamem
Later from Actinogen Medical
- December 2017 Quarterly Report
- New Data Supports Cortisol Hypothesis
- Strong Recruitment Progress in Alzheimers Trial
- Mid-Way Point Reached in Landmark Alzheimers Trial - XanADu
- March 2018 Quarterly Report
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical